Arvinas (ARVN) EBITDA Margin (2017 - 2026)
Arvinas (ARVN) recorded quarterly EBITDA Margin of 379.49% in Q1 2026, up 46.67% quarter-over-quarter from 711.58% in Q4 2025, and down 42366.0% on a YoY basis from N/an in Q1 2025.
Arvinas (ARVN) EBITDA Margin (2017 - 2026) Analysis & Trends
Arvinas' EBITDA Margin history runs 10 years deep, the most recent figure standing at 379.49% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 42366.0% year-over-year to 379.49%; the TTM figure through Mar 2026 stood at 249.66% (down 24013.0% YoY), while the FY2025 annual figure was 30.69%, up 4326.0% from the prior year.
- EBITDA Margin was 379.49% for Q1 2026 at Arvinas, up from 711.58% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 345.01% in Q4 2023 to a low of 711.58% in Q4 2025.
- Historically, EBITDA Margin has averaged 173.97% across 5 years, with a median of 204.23% in 2022.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin surged 70132 bps in 2022, then sank 63016 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 204.23% in 2022, then jumped by 269 bps to 345.01% in 2023, then tumbled by 124 bps to 81.42% in 2024, then tumbled by 774 bps to 711.58% in 2025, then jumped by 47 bps to 379.49% in 2026.
- The last three EBITDA Margin figures came in at 379.49% (Q1 2026), 711.58% (Q4 2025), and 82.82% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -379.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -379.49% |
| Dec 31, 2025 | -711.58% |
| Sep 30, 2025 | -82.82% |
| Jun 30, 2025 | -275.45% |
| Mar 31, 2025 | 44.17% |
| Dec 31, 2024 | -81.42% |
| Sep 30, 2024 | -40.33% |
| Jun 30, 2024 | -45.23% |
| Mar 31, 2024 | -279.45% |
| Dec 31, 2023 | 345.01% |
| Sep 30, 2023 | -176.30% |
| Jun 30, 2023 | -121.47% |
| Mar 31, 2023 | -231.69% |
| Dec 31, 2022 | -204.23% |
| Sep 30, 2022 | -207.83% |
| Jun 30, 2022 | -216.86% |
| Mar 31, 2022 | -292.45% |
| Dec 31, 2021 | -171.69% |
| Sep 30, 2021 | -504.30% |
| Jun 30, 2021 | -918.18% |